The rising worldwide cancer burden is likely to fuel the development of the cytokine market globally over the forecast period. Because cytokines can influence the host immune response to cancer cells and trigger tumor cell death, cytokine-based immunotherapy is a potential field in cancer treatment. The increasing amount of diagnostic, therapeutic, and prophylactic cytokine applications is likely to drive the worldwide cytokine market over the forecast period. Increased R&D and clinical trials, as well as the COVID-19 (global pandemic) outbreak, are likely to provide attractive growth prospects. The high prices of cytokine-based medicines, as well as a lack of specificity, are projected to stifle expansion in the worldwide cytokine industry.
According to Coherent Market Insight, the global Cytokine Market was valued at US$ 77,796.1 Mn in 2021 and is forecast to reach a value of US$ 141,667.1 Mn by 2028 at a CAGR of 8.9%between 2022 and 2028.
Key Leaders in the Cytokine Industry:
Biocon Limited
Biocon Limited, a biopharmaceutical company, manufactures pharmaceuticals, and medicinal chemical and botanical products. The company operates through Generics, Novel Biologics, Biosimilars, and Research Services segments. It focuses in the areas of diabetes, oncology, immunology, ophthalmology, and bone health diseases. Biocon Limited was founded in 1978 and is headquartered in Bengaluru, India.
Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company was founded in 1886 and is based in New Brunswick, New Jersey. On October 2022, The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's therapy for treating a type of multiple myeloma, the company said on Tuesday, giving another treatment option to patients with the incurable blood cancer.
Abbvie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc.
UCB S.A.
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company was incorporated in 1925 and is headquartered in Brussels, Belgium. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally. T
Astra Zeneca PLC
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153.